Consider the following before gently correcting your loved one: The present stage of dementia and your loved one’s ability to process information.; Is the behavior connected to dementia, or was it ...

“This is excellent news for the 3+ million Americans currently taking lithium-based treatments,” Stephan Jackman, CEO of Alzamend, said in a press release.. AL001 (also known as LiProSal) is an ionic ...

While there is no cure for Alzheimer’s disease, nor have any disease-modifying therapies been approved yet, there are several medications available by prescription to treat disease symptoms that ...

“This first regulatory approval for AlzoSure Predict … represents a significant advance for the millions of patients and their families in Europe at risk from Alzheimer’s disease,” Paul Kinnon, CEO of ...

“In the care home, I really wanted Jelly Drops to tackle dehydration and also to be really fun and engaging and sort of a social tool in the care home as well,” Hornby said in a video interview with ...

Alzheimer’s disease (AD) is associated with a gradual decline in memory and mental ability, due to the accumulation and spread of damage in the brain. It is an irreversible condition, with symptoms ...

Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...

According to a 2013 article published in Administration and Policy in Mental Health, “Public stigma is a pervasive barrier that prevents many individuals in the U.S. from engaging in mental health ...

The AI model, called Passive Digital Marker (PDM), was developed and tested by researchers at Purdue University and Indiana University with the aim of predicting dementia prior to disease onset in a ...

For the first time, the beneficial effects of pure maple syrup were included in the natural products that protect brain cells against the neural damage found in patients with Alzheimer’s disease. Dr.

Alzamend Neuro has requested approval from the U.S. Food and Drug Administration (FDA) to begin clinical trials to test AL001, its investigational lithium-based ionic cocrystal oral therapy for ...

The global Phase 2b/3 trial, called Anavex 2-73-AD-004 (NCT03790709), enrolled 509 people, ages 60-85, with mild cognitive impairments or mild dementia due to Alzheimer’s.The participants were ...